Fred Grossman
President & Chief Medical Officer Coya Therapeutics
Seminars
Thursday 26th March 2026
Enhancing Tregs to Potentially Halt ALS Progression & Unlock new Neurodegenerative Treatment Paths
1:30 pm
- Stimulating regulatory T cells to counter immune dysregulation and address a core driver of ALS disease progression
- Providing data supporting Coya's combination of Low Dose IL-2 + CTLA4-Ig to potentially halt ALS disease progression
- Exploring clinical trial design towards potential FDA approval
